A HIV prevention drug won't be taxpayer-subsidised after a committee decided not to recommend its listing on the Pharmaceutical Benefits Scheme.
An application to list Truvuda - a once-daily pill which costs around $750 a month and aimed at preventing HIV transmission - was rejected on Friday.
The Australian Federation of AIDS Organisations said it was disappointed with the decision, adding people were needlessly getting HIV while waiting to access the pill.
Share
